Retapamulin, a topical pleuromutilin antibiotic, is the first in a new class of topical
antibiotics approved for human use. In the European Union (EU), retapamulin is approved for
the treatment of impetigo and secondarily-infected traumatic lesions in persons nine or more
months of age. This study is designed to examine retapamulin use in the pediatric population
less than nine months of age. We will conduct a five-year assessment of prescriptions for
retapamulin using the General Practice Research Database. For each year of reporting, the
observed frequencies of prescriptions of retapamulin, with or without same-day
co-prescriptions of topical mupirocin or fusidic acid, will be identified. The five-year
reporting period will include five years of distinct, non-overlapping, non-cumulative
prescription use of first exposure to retapamulin, with or without same-day co-prescription
of topical mupirocin or fusidic acid.